A retrospective study of the time to clinical endpoints for advanced prostate cancer

BJU International

Volumn 96, Issue 7, 2005, Pages 985-989

  Sharifi, Nima ^a   Dahut, William L ^a   Steinberg, Seth M ^a   Figg, William D ^a   Tarassoff, Christopher ^a   Arlen, Philip ^a   Gulle, James L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Natural history; Prostatic neoplasms; PSA; Retrospective study; Survival analysis

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; GLEASON SCORE; HUMAN; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 27444435258     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05798.x     Document Type: Article

References (18)

1. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24
2. Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42
3. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506-13
4. Smaletz O, Scher HI, Small EJ et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20: 3972-82
5. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-7
6. Oefelein MG, Agarwal P, Resnick MI. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 2004; 171: 1525-8
7. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7
8. Shulman MJ, Benaim EA. The natural history of androgen independent prostate cancer. J Urol 2004; 172: 141-5
9. Smith M, Kabbinavar F, Saad F et al. Natural history of rising serum PSA in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 2918-25
10. Sharifi N, Gulley JL, Dahut WL Androgen deprivation therapy for prostate cancer. JAMA 2005; 205: 238-44
11. Partin AW, Pound CR, Rootselaar CV, Epstein JI, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy: Update. J Urol 2003; 169: 241-2
12. Fujikawa K, Matsui Y, Fukuzawa S, Takeuchi H. Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma. Eur Urol 2000; 37: 218-22
13. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
14. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20
15. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308
16. Gregory CW, Fei X, Ponguta LA et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004; 279: 7119-30
17. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004; 11: 459-76
18. Sharifi N, Farrar WL. Androgen receptor as a therapeutic target for hormone refractory prostate cancer. Am J Ther 2005; in press